Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-07

Clinical Trial Update: Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the neurocognitive effects of alirocumab (Praluent) versus placebo in hypercholesterolemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Praluent (alirocumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Hypercholesterolemia | Phase 4 | Status: COMPLETED | Results posted: 2021-05-07